Page 2 - Sun Pharma

Sun Pharma stock slips 2% in firm market, nears 52-week low; here's why

Thus far in the calendar year 2025, Sun Pharma stock has underperformed the market by falling nearly 17 per cent, as compared to 2 per cent rise in the BSE Sensex.

Sun Pharma slips 5% in 2 days, nears 52-wk low; why drug stock trades weak?

Thus far in August 2025, Sun Pharma has underperformed the market by falling 8 per cent, as compared to a 1 per cent decline in the BSE Sensex

Sun, Lupin, Dr Reddy's drop up to 4%; why are pharma stocks falling today?

Pharma shares crash: In the past four weeks, the Nifty Pharma index has slipped 5 per cent, as against 0.19 per cent decline in the Nifty 50.

Sensex down 260 pts, Nifty below 24,700; FMCG lead gains, pharma drags

Majority of stocks from the Sensex pack were trading in red with Sun Pharma, Tata Steel, Tata Motors, Infosys and Tech Mahindra among the top laggards.

Tariff worries, Sun Pharma Q1 miss: Why are pharma stocks falling today?

Pharma stocks came under pressure after President Trump announced a 25 per cent tariff rate for Indian exports to the US

Sun Pharma Q1 net profit falls 20% Y-o-Y; revenue rises 9%

Litigation, drug discontinuation weigh on earnings; US market remains sluggish even as India sales and Leqselvi launch boost specialty push

Sun Pharma Q1 results: PAT dips 20% to ₹2,279 crore; revenue rises 8.6%

Sun Pharmaceutical Industries on Thursday said its consolidated net profit declined 20 per cent year-on-year to Rs 2,279 crore for the first quarter ended June 30, 2025. The Mumbai-based drug major posted a net profit of Rs 2,836 crore for the April-June quarter of the last financial year. Adjusted net profit, excluding the exceptional items, for the first quarter stood at Rs 2,996 crore, up 6 per cent year-on-year. Total income rose to 14,316 crore for the June quarter as against Rs 13,185 crore in the year-ago period, Sun Pharma said in a regulatory filing. Sun Pharma Chairman and Managing Director Dilip Shanghvi said the drug maker had a strong performance during the quarter, where the overall growth reflects steady progress across all its markets. "India continues to show strong momentum, contributing meaningfully to our performance. The US launch of LEQSELVI represents an important step forward, offering a new treatment option for patients with severe alopecia areata," he ...

Here's why Apollo Hospitals & 2 other stocks are on analyst radar today

Stocks to buy: Analyst at Religare recommends Sun Pharma, Apollo Hospitals; Check target price, stop loss here

Sun Pharma, Lupin, Dr Reddy's recall products in US due to mfg issues

Domestic drug majors Sun Pharma, Lupin and Dr Reddy's Laboratories are recalling drugs in the US market due to manufacturing issues and product mix up, according to the US health regulator. As per the latest Enforcement Report of US Food and Drug Administration (USFDA), the Mumbai-headquartered Sun Pharmaceutical Industries is recalling 5,448 bottles of a generic medication in the US. Princeton-based Sun Pharmaceutical Industries Inc is recalling the affected lot of Lisdexamfetamine Dimesylate capsules (60 mg) due to "Failed Dissolution Specifications", the US health regulator stated. The medication is used to treat attention deficit hyperactivity disorder (ADHD). The drug firm initiated the Class II recall in the US on June 16 this year, it added. Another Mumbai-based drug maker Lupin is recalling 58,968 bottles of a generic combination medication used to treat high blood pressure. Naples-based Lupin Pharmaceuticals Inc is recalling Lisinopril and Hydrochlorothiazide tablets (US

Sun Pharma resolves US antitrust case with $200 mn agreement

Sun Pharmaceutical Industries on Thursday said it has settled an antitrust litigation in the US entailing a payment of USD 200 million. The subsidiaries of the company, Sun Pharmaceutical Industries, Inc. (SPII) and Taro Pharmaceuticals USA, Inc. have signed a settlement agreement with the End Purchaser Plaintiffs in the In re Generic Pharmaceuticals Pricing Antitrust Litigation in the Eastern District of Pennsylvania, US, the Mumbai-based drugmaker said in a regulatory filing. "Under the terms of the settlement agreement, the subsidiaries will make an aggregate payment of USD 200 million in exchange for a full release of all claims asserted against them in the End Purchaser Action by the settlement class members," it added. The settlement amounts may be reduced if more than a certain percentage of the total insured class members opt out of the putative class, the company stated. The settlement agreement is subject to court approval, it added.

Results preview: Pharma firms stare at muted earnings growth for Q1

Indian pharma firms are set to post modest Q1FY26 earnings, with Revlimid erosion impacting US revenues and domestic growth moderating in chronic therapies

Sun Pharma's psoriasis drug delivers positive results in arthritis trials

Phase 3 trials show ILUMYA improved PsA symptoms significantly, with no new safety concerns; results support potential regulatory submissions in the US and globally

Sun Pharma gains on US launch of Leqselvi, analysts see strong upside

Sun Pharma rises 2.7% as it launches Leqselvi in US following settlement with Incyte, with analysts projecting $200-300 million revenue from the drug in 3-5 years

Sun Pharma shares rise 2% on US launch of hair loss drug after settlement

Sun Pharma shares rose nearly 2 per cent on Tuesday after the company launched Leqselvi, a new treatment for severe alopecia areata

Sun Pharma launches Leqselvi in US after patent settlement with Incyte Corp

Sun Pharma will pay Incyte an upfront fee and royalties to market Leqselvi in the US for alopecia areata until patent expiry in FY26 following a litigation settlement

Sun Pharma launches hair loss drug Leqselvi in US after patent settlement

The delay in Sun Pharma's launch of Leqselvi in the US was caused by a patent infringement case, which was later settled in a US court with Incyte Corp

Price pressures to intensify for drugmakers, says Sun Pharmaceutical

Sun Pharma expects global pricing strain due to policy shifts, as FY25 US sales rise 5.8% despite compliance challenges; specialty business lifts overall growth

Sun Pharma partner Philogen withdraws EU application for skin cancer drug

Experts believe that the drug still holds potential for future market entry, and the current development should be viewed as a temporary setback

Abbott, MSD join hands to distribute key diabetic drug across India

Abbott to distribute MSD's sitagliptin portfolio-Januvia, Janumet, Janumet XR-in India, targeting deeper reach in the ₹950-1,000 crore diabetes drug segment

Sun Pharma share slips 2% as USFDA flags 8 observations for Halol facility

Sun Pharma shares dropped in trade after the company announced that United States Food and Drug Administration (USFDA) has issued a Form-483, with 8 observations for its Halol facility in Gujarat.